See more : Aeris Environmental Ltd (AEI.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Tevogen Bio Holdings Inc. (TVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tevogen Bio Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 10X Capital Venture Acquisition Corp. III (VCXB) Income Statement Analysis – Financial Results
- Malaysia Smelting Corporation Berhad (5916.KL) Income Statement Analysis – Financial Results
- Harbin Xinguang Optic-Electronics Technology Co.,Ltd. (688011.SS) Income Statement Analysis – Financial Results
- China Customer Relations Centers, Inc. (CCRC) Income Statement Analysis – Financial Results
- Vodatel Networks Holdings Limited (8033.HK) Income Statement Analysis – Financial Results
Tevogen Bio Holdings Inc. (TVGN)
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 5.77M | 2.96M |
| General & Administrative | 2.27M | 953.08K | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.27M | 953.08K | 1.66M |
| Other Expenses | 0.00 | -7.38M | -10.38M |
| Operating Expenses | 2.27M | 953.08K | 4.62M |
| Cost & Expenses | 2.27M | 953.08K | 4.62M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 256.03K | 0.00 | 598.50K |
| Depreciation & Amortization | 197.55K | 230.82K | 9.38K |
| EBITDA | 188.71K | -953.08K | -28.75K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.84K | -13.72M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -58.48K | 4.42M | -15.59M |
| Income Before Tax | -67.33K | 4.41M | -15.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -230.82K | -9.78M |
| Net Income | -67.33K | 4.41M | -15.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.04 | -0.13 |
| EPS Diluted | 0.00 | 0.04 | -0.13 |
| Weighted Avg Shares Out | 165.42M | 120.00M | 120.00M |
| Weighted Avg Shares Out (Dil) | 165.42M | 120.00M | 120.00M |
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line...
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion
WARREN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- HMP Partners and The Patel Family LLP, leading investors in innovative healthcare ventures, congratulate Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) and founding CEO Dr. Ryan Saadi for being...
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, elaborates on developing TVGN...
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use
WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today highlights the publication...
Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders...
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024
WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to share its...
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its...
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation
WARREN, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today reissues its previously...
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company's ambition...
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Tevogen Bio Inc (Nasdaq: TVGN), please note that paragraph two has been updated.
Source: https://incomestatements.info
Category: Stock Reports